Korean J Thorac Cardiovasc Surg.
1999 Dec;32(12):1093-1099.
Valvuloplasy in Mitral Regurgitation: available option in Young rheumatic
mitral regurgitation patients
- Affiliations
-
- 1Department of Thoracic and Cardiovascular Surgery,
Asan Medical Center, University of Ulsan.
- 2Department of Thoracic and Cardiovascular Surgery, Kang Nung Hospital.
Abstract
-
BACKGROUND: The present study was undertaken to assess the effectiveness of surgical repair
as a method of treatment for rheumatic mitral regurgitation by comparing the results of mitral
valvuloplasty(MVP) in rheumatic mitral regurgitation and degenerative mitral regurgitation.
MATERIAL AND METHOD: Among the 184 MVP patients between January 1995 to December 1998,
49 Rheumatic mirtal regurgiation patients(Group I) and 72 degenerative mirtal
regurgitation(Group II) patients were studied. The mean age in group I was 36.3+/-14.6(16-74)
and in group II, 52.5+/-13.4(14-77) years. The total follow up duration was 72.2patient years
for group I and 77.2 patient years for group II. The Echocardiography was performed
preoperatively, at 6months and 1 year postoperatively, and then yearly thereafter in both
groups.
RESULT: Preoperatively, there were no hemodynamic differences between the two groups.
The preoperative mitral regurgitation was 3.9+/-0.4 in group I and 3.9+/-0.3 in group II,
but on follow up, both groups showed decrease of grade of regurgitation to 0.9+/-0.9 in
group I and 0.8+/-0.7 in group II. The mitral valve area or the mean transmitral pressure
gradient was not significantly different between the two groups. There was neither early
nor late mortality in either group and the reoperation rate in group I was 1.4% per patient
year and 2.6% per patient year in group II. The rate of thromboembolism in group I was 2.8%
per patient year and 1.3% per patient year in group II. There was one bacterial endocarditis
in group I. Statistical analysis of the data between the two groups failed to reveal any
significant differences.
CONCLUSION
Although the results of a long term follow up will be required, the current
intermedite term study showed that repair was a viable option in the treatment of rheumatic
mitral regurgitation.